Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound

Lipids

Volumn 41, Issue 4, 2006, Pages 371-380

  Park, Cheon Ho ^a   Nguyen, Su Duy ^a   Kim, Mee Ree ^a   Jeong, Tae Sook ^b   Sok, Dai Eun ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLS; AMINES; BINDING ENERGY; COMPUTER SIMULATION; ENZYME INHIBITION; ENZYMES; FLUORESCENCE; MICELLES; PHOSPHOLIPIDS;

DIMYRISTOYLPHOSPHATIDYLCHOLINE (DMPC); LYSOPHOSPHATIDYLINOSITOL (LYSOPI); PALMITOYL-LYSOPHOSPHATIDYLGLYCEROL (PALMITOYL-LYSOPG); PARAOXONASE 1 (PON1);

BIODIVERSITY;

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; DIAZOXONASE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIMYRISTOYLPHOSPHATIDYLSERINE; ESTERASE; HIGH DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; PALMITOYLLYSOPHOSPHATIDIC ACID; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PURIFICATION; FLUORESCENCE; HUMAN; MICELLIZATION; MOLECULAR INTERACTION; NORMAL HUMAN;

APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; BINDING SITES; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ENZYME INHIBITORS; FLUORESCENCE; HUMANS; LIPIDS; LIPOSOMES; LYSOPHOSPHOLIPIDS; SOLUBILITY; TRYPTOPHAN;

EID: 33745130045     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-006-5108-4     Document Type: Article

References (51)

1. Gan, K.N., Smolen, A., Eckerson, H.W., and La Du, B.N. (1991) Purification of Human Serum Paraoxonase/Arylesterase, Drug Metab. Dispos. 19, 100-106.
2. Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer, L.L., Edwards, P.A., Watson, A.D., and Lusis, A.J. (1995). Atherosclerosis: Basic Mechanism, Oxidation, Inflammation and Genetics, Circulation 91, 2488-2496.
3. Mackness, M.I., Mackness, B., Durrington, P.N., Connelly, P.W., and Hegele, R.A. (1996) Paraoxonase: Biochemistry, Genetics and Relationship to Plasma Lipoproteins, Curr. Opin. Lipidol. 7, 69-76.
4. La Du, B.N. (1996) Structural and Functional Diversity of Paraoxonase, Nat. Med. 2, 1186-1187.
5. Davies, H., Richter, G., Keifer, R.J., Broomfield, M., Sowalla, C.A., and Furlong, C.E. (1996) The Effect of the Human Serum Paraoxonase Polymorphism Is Reversed with Diazoxon, Soman and Sarin, Nat. Genet. 14, 334-336.
6. Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., and La Du, B.N. (2000) Human Serum Paraoxonase (PON1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters, Drug Metab. Dispos. 28, 1335-1342.
7. Teiber, J.F., Draganov, D.I., and La Du, B.N. (2003) Lactonase and Lactonizing Activities of Human Serum Paraoxonase (PON1) and Rabbit Serum PON3, Biochem. Pharmacol. 66, 887-896.
8. Shih, D.M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Kama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M., and Lusis, A.J. (1998) Mice Lacking Serum Paraoxonase Are Susceptible to Organophosphate Toxicity and Atherosclerosis, Nature 394, 284-287.
9. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton, R.S., and La Du, B.N. (1999) Human Serum Paraoxonase (PON 1) Is Inactivated by Oxidized Low Density Lipoprotein and Preserved by Antioxidants, Free Radic. Biol. Med. 26, 892-904.
10. Mackness, B., Davies, G.K., Turkic, W., Lee, E., Roberts, D.H., Hill, E., Roberts, C., Durrington, P.N., and Mackness, M.I. (2001) Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype?, Arterioscler. Thromb. Vasc. Biol. 21, 1451-1457.
11. Rozenberg, O., Shih, D.M., and Aviram, M. (2003) Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis: Possible Role for Its Phospholipase-A2-like Activity and Lysophosphatidylcholine Formation, Arterioscler. Thromb. Vasc. Biol. 23, 461-467.
12. Mackness, B., Hine, D., Liu, Y., Mastorikou, M., and Mackness, M. (2004) Paraoxonase-1 Inhibits Oxidised LDL-Induced MCP-1 Production by Endothelial Cells, Biochem. Biophys. Res. Commun. 318, 680-683.
13. Ruiz, J., Blanche, H., James, R.W., Garin, M.C., Vaisse, C., Charpentier, G., Cohen, N., Morabia, A., Passa, P., and Froguel, P. (1995) Gln-Arg192 Polymorphism of Paraoxonase and Coronary Heart Disease in Type 2 Diabetes, Lancet 30, 869-872.
14. Shih, D.M., Gu, L., Kama, S., Xia, Y.-R., Navab, M., Fogelman, A.M., and Lusis, AJ. (1996) Genetic Dietary Regulation of Serum Paraoxonase Expression and Its Role in Atherogenesis in a Mouse Model, J. Clin. Invest. 97, 1630-1639.
15. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., and Rosenblat, M. (2000) Human Serum Paraoxonase (PON 1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions: PON1 Esterase and Peroxidase-like Activities, Circulation 101, 2510-2517.
16. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., and Mackness, M. (2003) Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study, Circulation 107, 2775-2779.
17. Marathe, G.K., Zimmerman, G.A., and McIntyre, T.M. (2003) PAF Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles, J. Biol. Chem. 278, 3937-3947.
18. Connelly, P.W., Draganov, D., and Maguire G.F. (2005) Paraoxonase-1 Does Not Reduce or Modify Oxidation of Phospholipids by Peroxynitrite, Free Radic. Biol. Med. 38, 164-174.
19. Rosenblat, M., Vaya, J., Shih, D., and Aviram, M. (2005) Paraoxonase 1 (PON1) Enhances HDL-Mediated Macrophage Cholesterol Efflux via the ABCA1 Transporter in Association with Increased HDL Binding to the Cells: A Possible Role for Lysophosphatidylcholine, Atherosclerosis 179, 69-77.
20. Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D.S., and Aviram, M. (2006) The Catalytic Histidine Dyad of High Density Lipoprotein-Associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-Mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol Efflux, J. Biol. Chem. 281, 7657-7665.
21. Sorenson, R.C., Bisgaier, C.L., Aviram, M., Hsu, C., Billecke, S., and La Du, B.N. (1999) Human Serum Paraoxonase/Arylesterase's Retained Hydrophobic N-terminal Leader Sequence Associates with HDLs by Binding Phospholipids: Apolipoprotein A-I Stabilizes Activity, Arterioscler. Thromb. Vasc. Biol. 19, 2214-2225.
22. Kuo, C.-L., and La Du, B.N. (1995) Comparison of Purified Human and Rabbit Serum Paraoxonases, Drug Metab. Dispos. 23, 935-944.
23. James, R.W., and Deakin, S.P. (2004) The Importance of High-Density Lipoproteins for Paraoxonase-1 Secretion, Stability, and Activity, Free Radic. Biol. Med. 37, 1986-1994.
24. Echjkerson, H.W., Wyle, C.M., and La Du, B.N. (1983) The Human Serum Paraoxonase/Arylesterase Polymorphism, Am. J. Hum. Genet. 35, 1126-1138.
25. Bargota, R.S., Akhtar, M., Biggadike, K., Gani, D., and Allemann, R.K. (2003) Structure-Activity Relationship on Human Serum Paraoxonase (PON1) Using Substrate Analogues and Inhibitors, Bioorg. Med. Chem. Lett., 13, 1623-1626.
26. Adkins, S., Gan, K.N., Mody, M., and La Du, B.N. (1993) Molecular Basis for the Polymorphic Forms of Human Serum Paraoxonase/Arylesterase: Glutamine or Arginine at Position 191 for the Respective A or B Allozymes, Am. J. Hum. Genet. 52, 598-608.
27. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R.B., McCarthy, A., Toker, L., Silman, I., Sussman, J.L., and Tawfik, D.S. (2004) Structure and Evolution of the Serum Paraoxonase Family of Detoxifying and Anti-atherosclerotic Enzymes, Nat. Struct. Mol. Biol. 11, 412-419.
28. James, R.W., Blatter Garin, M.C., Calabresi, L., Miccoli, R., von Eckardstein, A., Tilly-Kiesi, M., Taskinen, M.R., Assmann, G., and Franceschini, G. (1998) Modulated Serum Activities and Concentrations of Paraoxonase in High Density Lipoprotein Deficiency States, Atherosclerosis 139, 77-82.
29. Paragh, G., Balla, P., Katona, E., Seres, I., Egerhazi, A., and Degrell, I. (2002) Serum Paraoxonase Activity Changes in Patients with Alzheimer's Disease and Vascular Dementia, Eur. Arch. Psychiatry Clin. Neurosci. 252, 63-67.
30. Letellier, C., Durou, M.R., Jouanolle, A.M., Le Gall, J.Y., Poirier, J.Y., and Ruelland, A. (2002) Serum Paraoxonase Activity and Paraoxonase Gene Polymorphism in Type 2 Diabetic Patients with or without Vascular Complications, Diabetes Metab. 28, 297-304.
31. Jarvik, G.P., Hatsukami, T.S., Carlson, C., Richter, R.J., Jampsa, R., Brophy, V.H., Margolin, S., Rieder, M., Nickerson, D., Schellenberg, G.D., Heagerty, P.J., and Furlong, C.E. (2003) Paraoxonase Activity, but Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease, Arterioscler. Thromb. Vasc. Biol. 23, 1465-1471.
32. James, R.W., Leviev, I., and Righetti, A. (2000) Smoking Is Associated with Reduced Serum Paraoxonase Activity and Concentration in Patients with Coronary Artery Disease, Circulation 101, 2252-2257.
33. Senti, M., Tomas, M., Fito, M., Weinbrenner, T., Covas, M.I., Sala, J., Masia, R., and Marrugat, J. (2003) Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome, J. Clin. Endocrinol. Metab. 88, 5422-5426.
34. Nguyen, S.D., and Sok, D.-E. (2004) Preferential Inhibition of Paraoxonase Activity of Human Paraoxonase 1 by Negatively-Charged Lipids, J. Lipid Res. 45, 2211-2220.
35. Nguyen, S.D., and Sok, D.-E. (2003) Beneficial Effect of Oleoylated Lipids on Paraoxonasel: Protection Against Oxidative Inactivation and Stabilization, Biochem. J. 375, 275-285.
36. Josse, D., Ebel, C., Stroebel, D., Fontaine, A., Borges, F., Echalier, A., Baud, D., Renault, F., LeMaire, M., Chabrieres, E., and Masson, P. (2002) Oligomeric States of the Detergent-Solubilized Human Serum Paraoxonase (PON1), J. Biol Chem. 277, 33386-33397.
37. Epand, R.M., Epand, R.F., Sayer, B.G., Melacini, G., Palgulachari, M.N., Segrest, J.P., and Anantharamaiah, G.M. (2004) An Apolipoprotein AI Mimetic Peptide: Membrane Interactions and the Role of Cholesterol, Biochemistry 43, 5073-5083.
38. Stafford, R.E., Fanni, T., and Dennis, E.A. (1989) Interfacial Properties and Critical Micelle Concentration of Lysophospholipids, Biochemistry 28, 5113-5120.
39. La Du, B.N., Adkins, S., Kuo, C.L., and Lipsig, D. (1993) Studies on Human Serum Paraoxonase/Arylesterase, Chem.-Biol. Interact. 87, 25-34.
40. Yeung, D.T., Josse, D., Nicholson, J.D., Khanal, A., McAndrew, C.W., Bahnson, B.J., Lenz, D.E., and Cerasoli, D.M. (2004) Structure/Function Analyses of Human Serum Paraoxonase (HuPON1) Mutants Designed from a DFPase-like Homology Model, Biochim. Biophys. Acta 1702, 67-77.
41. Garavito, R.M., and Ferguson-Miller, S. (2001) Detergents as Tools in Membrane Biochemistry, J. Biol. Chem. 276, 32403-32406.
42. Rankin, S.E., Watts, A., and Pinheiro, T.J.T. (1998) Electrostatic and Hydrophobic Contributions to the Folding Mechanism of Apocytochrome c Driven by the Interaction with Lipid, Biochemistry 37, 12588-12595.
43. Gaidukov, L., and Tawfik, D.S. (2005) High Affinity, Stability, and Lactonase Activity of Serum Paraoxonase PON1 Anchored on HDL with ApoA-I, Biochemistry 44, 11843-11854.
44. Oda, M.N., Bielicki, J.K., Berger, T., and Forte, T.M. (2001) Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity, Biochemistry 40, 1710-1718.
45. Zschornig, O., Pietsch, M., Suss, R., Schiller, J., and Gutschow, M. (2005) Cholesterol Esterase Action on Human High Density Lipoproteins and Inhibition Studies: Detection by MALDI-TOF MS, J. Lipid Res. 46, 803-811.
46. Shen, Z., Wu, M., Elson, P., Kennedy, A.W., Belinson, J., Casey, G., and Xu, Y. (2001) Fatty Acid Composition of Lysophosphatidic Acid and Lysophosphatidylinositol in Plasma from Patients with Ovarian Cancer and Other Gynecological Diseases, Gynecol. Oncol. 83, 25-30.
47. Francone, O.L., Subbaiah, P.V., van Tol, A., Royer, L., and Haghpassand, M. (2003) Abnormal Phospholipid Composition Impairs HDL Biogenesis and Maturation in Mice Lacking Abca1, Biochemistry 42, 8569-8578.
48. Ishimoto, Y., Yamada, K., Yamamoto, S., Ono, T., Notoya, M., and Hanasaki, K. (2003) Group V and X Secretory Phospholipase A(2)s-Induced Modification of High-Density Lipoprotein Linked to the Reduction of Its Antiatherogenic Functions, Biochim. Biophys. Acta. 1642, 129-138.
49. Benitez, S., Sanchez-Quesada, J.L., Ribas, V., Jorba, O., Blanco-Vaca, F., Gonzalez-Sastre, F., and Ordonez-Llanos, J. (2003) Platelet-Activating Factor Acetylhydrolase Is Mainly Associated with Electronegative Low-Density Lipoprotein Subfraction, Circulation 8, 92-96.
50. Murakami, M., and Kudo, I. (2003) New Phospholipase A2 Isozymes with a Potential Role in Atherosclerosis, Curr. Opin. Lipid. 14, 431-436.
51. Getz, G.S., and Reardon, C.A. (2004) Paraoxonase, a Cardioprotective Enzyme: Continuing Issues, Curr. Opin. Lipidol. 15, 261-267.